The p53 protein is among the most effective of the body's natural defences against cancer. News comes of a promising way of releasing the protein from its inhibitions to carry out its anti-tumour duties.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction
International Journal of Peptide Research and Therapeutics Open Access 15 March 2006
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lane, D. P. & Crawford, L. V. Nature 278, 261–263 (1979).
Vousden, K. H. & Lu, X. Nature Rev. Cancer 2, 594–604 (2002).
Surendran, A. Nature Med. 10, 9 (2004).
Snyder, E. L. et al. PLoS Biol. doi: 10.1371/journal.pbio.0020036 (2004).
Vassilev, L. T. et al. Science 303, 844–848 (2004).
Gudkov, A. V. & Komarova, E. A. Nature Rev. Cancer 3, 117–129 (2003).
Iwakuma, T. & Lozano, G. Mol. Cancer Res. 1, 993–1000 (2003).
Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Nature 378, 203–206 (1995).
Chene, P. Nature Rev. Cancer 3, 102–109 (2003).
Mendrysa, S. M. et al. Mol. Cell. Biol. 23, 462–473 (2003).
O'Leary, K. A. et al. Mol. Cell. Biol. 24, 186–191 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lane, D., Fischer, P. Turning the key on p53. Nature 427, 789–790 (2004). https://doi.org/10.1038/427789a
Issue Date:
DOI: https://doi.org/10.1038/427789a
This article is cited by
-
The effect of pre-low-dose X-ray radiation on tumor inhibition of HepG2 cells in tumor-bearing nude mice
The Chinese-German Journal of Clinical Oncology (2012)
-
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
Oncogene (2011)
-
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Nature Chemical Biology (2006)
-
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction
International Journal of Peptide Research and Therapeutics (2006)
-
Wip-ing out cancer
Nature Genetics (2004)